Previous 10 | Next 10 |
Shares of Denmark-based biopharmaceutical company Orphazyme’s (ORPH) experienced extreme volatility this month due to the actions of retail traders that were triggered by discussions about the stock on social media platforms such as Reddit. After hitting its $4.75 all-time low on June ...
A lot of everyday investors recently lost a bundle betting that the Food and Drug Administration would approve an experimental drug from Orphazyme (NASDAQ: ORPH) . There were reasons to suspect arimoclomol might earn approval to treat a rare life-threatening disease. There were also...
Investing in Penny Stocks in Summer 2021 Penny stocks are some of the hottest commodities of the year. With massive rises in value in only a short time frame and low prices, penny stocks remain popular among all types of investors. While these stocks have gotten a bad rap over the p...
Gainers: Geron (GERN) +48%.CAI International (CAI) +46%.Sykes Enterprises (SYKE) +30%.PDS Biotechnology (PDSB) +18%.Smith & Wesson Brands (SWBI) +17%.Biophytis (BPTS) +13%.SemiLEDs (LEDS) +10%.Clean Energy Fuels (CLNE) +10%.Luokung Technology (LKCO) +10%.Vinco Ventures (BBIG) +9%.Los...
Shares of Orphazyme (NASDAQ: ORPH) , a clinical-stage biopharmaceutical company, are getting hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved ...
JHVEPhoto/iStock Editorial via Getty Images Danish biotech Orphazyme ([[ORPH]] -43.0%) has extended the pre-market losses after the FDA decision not to grant the approval for Arimoclomol the company’s experimental therapy for rare genetic disease Niemann-Pick Disease Type C ((NPC)). Cy...
Gainers: Geron (GERN) +22%, AnPac Bio-Medical Science (ANPC) +20%, CureVac (CVAC) +13%, Crinetics Pharmaceuticals (CRNX) +7%, Seres Therapeutics (MCRB) +7%.Losers: Orphazyme (ORPH) -41%, Athira Pharma (ATHA) -41%, Chinook Therap...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GEO Group (NYSE: GEO ) is heading higher on Friday following news that the company’s CEO acquired shares of the stock. Source: JosephRouse / Shutterstock.com According to a recent filing with the U.S. S...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orphazyme (NASDAQ: ORPH ) is getting off to a rough start on Friday, with ORPH stock down more than 50% in pre-market trading. This comes after the Denmark-based biotech company has rocketed higher in recent weeks. In...
Orphazyme (ORPH) -53% on FDA thumbs down for arimoclomol; cuts FY21 outlook.Athira Pharma (ATHA) -30% after the decision to place CEO on temporary leave.Capstone Green Energy (CGRN) -26% on $10M capital raiseCellect Biotechnology (APOP) -9%.Arrival (ARVL) -9...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...